Prodigy has been updated in April 2012 for the following clinical areas:
Action: Clinicians who see patients with any of these conditions may find the new and updated information useful when reviewing current clinical practice.
The Department of Health has announced earlier this year that prescription charges for England will rise by 25 pence to £7.65 with effect from 1st April 2012. Charges have already been abolished in Wales and Northern Ireland and Scotland planning.
The price for both the three and twelve month pre-payment certificates remain unchanged at £29.10 and £104.00 respectively. These represent good value for money for people who would be required to pay an NHS prescription charge and who expect to need 4 or more prescriptions in a 3 month period or 14 or more prescriptions in a year.
Action: Clinicians should be aware of the current prescription charge and also the value for money represented by pre-payment certificates.
The National Prescribing Centre has published a MeReC Bulletin (PDF), the third in a series of three, that focuses on the therapeutic areas of the QIPP agenda.
This bulletin focusses on type 2 diabetes and covers the following topics:
For each of these therapeutic topic areas within type 2 diabetes the evidence base is summarised and current prescribing data are reviewed.
Action: Clinicians who prescribe for patients with type 2 diabetes and who are striving to deliver value for money while maintaining or improving the quality of care will find this information is useful and informative.
The National Institute of Health and Clinical Excellence (NICE) has published new guidance on the use of dabigatran (Pradaxa®) in the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation (AF).
Dabigatran is recommended as an option, within its licensed indication, in people with non-valvular atrial fibrillation with one or more of the following risk factors:
It is recommended that the treatment initiation decision includes a discussion of the risks and benefits of dabigatran compared with warfarin.
It is also suggested that for patients who are already taking warfarin, the potential risks and benefits of switching to dabigatran are discussed with consideration of their level of international normalised ratio (INR) control.
Action: Clinicians should be aware of this new guidance and implement any necessary changes to practice.
Prodigy has been updated in March 2012 for the following clinical areas:
Action: Clinicians who see patients with any of these conditions may find the new and updated information useful when reviewing current clinical practice.
| « Newer Posts | Older Posts » |
Prescribing Advice for GPs is powered by
WordPress.
Subscribe for Free to our RSS Feed for New Entries.
Akismet has protected Prescribing Advice for GPs from 609,598 spam comments.
